Form 4: Lyra Therapeutics Director, Nancy Lynn Snyderman, Reports Acquisition of Restricted Stock Units

Director Nancy Lynn Snyderman reports the acquisition of 32,000 Restricted Stock Units (RSUs) in Lyra Therapeutics, Inc.

Summary

• Nancy Lynn Snyderman, a director of Lyra Therapeutics, Inc., filed a Form 4 to report changes in beneficial ownership.
• The report indicates that on May 14, 2025, Snyderman acquired 32,000 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of Lyra Therapeutics' common stock.
• The RSUs will vest 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026, or (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan.
• Following the reported transaction, Snyderman directly owns 32,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating a director's acquisition of RSUs, which could be seen as a positive sign but doesn't provide enough information to strongly influence sentiment.

Positives

• The acquisition of RSUs by a director could be interpreted as a sign of confidence in the company's future prospects.

Future Outlook

The vesting of the RSUs is contingent upon future events, including the company's annual meeting date, the specified date in 2026, or a change in control.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates changes in the holdings of a director at Lyra Therapeutics.

Stakeholder Impact

• The acquisition of RSUs by a director may have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Lyra Therapeutics, Nancy Lynn Snyderman, Restricted Stock Units, RSU, Form 4, Beneficial Ownership, Director, Securities, Vesting